Vero Biotech: Secures $50M in Funding

  • Vero Biotech LLC, an Atlanta, Georgia-based biotechnology company, closed a senior secured term loan of $50m
  • Runway Growth Capital provided the financing
  • Vero Biotech (formerly known as GeNO LLC), a biotechnology company focused on the design, development, and commercialization of next-generation products
  • The company also developed the GENOSYL® Delivery System (GENOSYL DS), a inhaled nitric oxide delivery system approved by the U.S. Food and Drug Administration (FDA)
  • The GENOSYL DS transforms the delivery and use of nitric oxide, a vasodilator proven to play a critical role in the care of patients with adult respiratory distress syndrome
  • The GENOSYL® Delivery System authorized by the U.S. FDA for expanded emergency use access for patients with cardiopulmonary complications
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Visa and Ramp Boost Bill Pay Automation with Agentic AI

New integration aims to streamline corporate expense management processes.Highlights: Visa and Ramp announce partnership to automate corporate bill...

TikTok Seeks Financial Services Licenses in Brazil, Expanding Digital Reach

The platform aims to tap into Brazil's growing fintech market.Highlights: TikTok is applying for financial services licenses in...

CaixaBank Strengthens Crypto Investment Services for Clients

The bank expands its offerings to include digital asset investments.Highlights: CaixaBank introduces cryptocurrency investment services to its clients.Clients...

Monzo Shuts Down US Business to Focus on European Expansion

The UK-based fintech firm redirects efforts towards Europe amid challenges.Highlights: Monzo announces the closure of its US business.The...